Clinical Trial Update: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

This is a Phase 3 long-term extension trial to evaluate the safety and tolerability of Admilparant in participants with pulmonary fibrosis; the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• Admilparant

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Pulmonary Fibrosis | Phase 3 | Status: NOT_YET_RECRUITING